Becton Dickinson announced that it has received 510(k) clearance from the FDA for the BD Vaginal Panel on the BD COR System, a diagnostic test that directly detects the three most common infectious causes of vaginitis using BD’s high-throughput molecular diagnostic platform for large laboratories.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BDX:
- Moody’s to appoint Vincent Forlenza chairman on April 18
- Becton Dickinson announces FDA market approval for BD Onclarity HPV Assay
- Becton Dickinson price target raised to $260 from $245 at Piper Sandler
- Becton Dickinson ups FY23 adjusted EPS view to $12.07-$12.32 from $11.85-$12.10
- BD Reports First Quarter Fiscal 2023 Financial Results